ID Source | ID |
---|---|
PubMed CID | 44825260 |
CHEMBL ID | 1233798 |
SCHEMBL ID | 1306055 |
MeSH ID | M0384933 |
Synonym |
---|
CHEMBL1233798 , |
6-chloro-3-[1-(4-chlorobenzyl)-4-phenyl-1h-imidazol-5-yl]-1h-indole-2-carboxylic acid |
K23 , |
SCHEMBL1306055 |
bdbm50436047 |
QZJRNGXHRQJBJH-UHFFFAOYSA-N |
6-chloro-3-(1-(4-chlorobenzyl)-4-phenyl-1h-imidazol-5-yl)-1h-indole-2-carboxylic acid |
EX-A435 |
wk23 |
Q27461854 |
pb12 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Protein Mdm4 | Homo sapiens (human) | Ki | 36.0000 | 5.8600 | 5.8600 | 5.8600 | AID1118053; AID1263036 |
Cellular tumor antigen p53 | Homo sapiens (human) | Ki | 18.4580 | 0.0030 | 1.0736 | 5.8600 | AID1118052; AID1118053 |
E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | Ki | 0.9176 | 0.0009 | 0.1981 | 1.2400 | AID1118052; AID1141060; AID1195739; AID1263035; AID754224 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1118052 | Inhibition of p53 interaction to MDM2 (unknown origin) by fluorescence polarization assay | 2011 | MedChemComm, , Volume: 2 | The p53-MDM2/MDMX axis - A chemotype perspective. |
AID754224 | Binding affinity to MDM2 (unknown origin) expressed in Escherichia coli BL21(DE3) after 30 mins by fluorescence polarization assay in presence of P4 peptide | 2013 | Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14 | Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2. |
AID1263035 | Competition binding affinity to MDM2 (unknown origin) using p53 mimicking peptide TSFAEYWNLLSP after 30 mins by fluorescence polarization assay | 2015 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 25, Issue:24 | 2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists. |
AID1263036 | Competition binding affinity to MDMX (unknown origin) using p53 mimicking peptide TSFAEYWNLLSP after 30 mins by fluorescence polarization assay | 2015 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 25, Issue:24 | 2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists. |
AID1195739 | Binding affinity to human MDM2 by fluorescence polarization assay | 2015 | Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3 | Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. |
AID1141060 | Displacement of fluorescent P4 peptide from recombinant human MDM2 (18 to 125) expressed in Escherichia coli BL21(DE3) RIL expression system after 30 mins by fluorescence polarization assay | 2014 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11 | Hot spot-based design of small-molecule inhibitors for protein-protein interactions. |
AID1118053 | Inhibition of p53 interaction to MDMX (unknown origin) by fluorescence polarization assay | 2011 | MedChemComm, , Volume: 2 | The p53-MDM2/MDMX axis - A chemotype perspective. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (56.57) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (20.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |